MEA Anthrax Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143110
- Pages: 225
-
Format:
Short Description
Middle East and Africa Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others),Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Definition:
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal fluid, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Market Segmentation:
Middle East and Africa anthrax treatment market is categorized based on type, route of administration and end user.
On the basis of type, Middle East and Africa anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax
On the basis of route of administration, Middle East and Africa anthrax treatment market is segmented into oral, parenteral and others
On the basis of end user, Middle East and Africa anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others
Market Players
The key market players for Middle East and Africa anthrax treatment market are listed below:
Alembic Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
Lupin
Teva Pharmaceutical Industries Ltd.
ARISTO Pharmaceuticals Private Limited
TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET 74
1.4 LIMITATIONS 76
1.5 MARKETS COVERED 76
2 MARKET SEGMENTATION 79
2.1 MARKETS COVERED 79
2.2 GEOGRAPHICAL SCOPE 80
2.3 YEARS CONSIDERED FOR THE STUDY 81
2.4 CURRENCY AND PRICING 81
2.5 DBMR TRIPOD DATA VALIDATION MODEL 82
2.6 MULTIVARIATE MODELLING 85
2.7 PRODUCT SEGMENT LIFELINE CURVE 85
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
2.9 DBMR MARKET POSITION GRID 87
2.10 MARKET APPLICATION COVERAGE GRID 88
2.11 VENDOR SHARE ANALYSIS 89
2.12 SECONDARY SOURCES 90
2.13 ASSUMPTIONS 90
3 EXECUTIVE SUMMARY 91
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 96
4.2 PORTERS FIVE FORCES 97
4.3 DEMOGRAPHIC TRENDS- 98
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 100
4.4.1 INCIDENCE 100
4.4.2 DEVELOPED COUNTRIES- 100
4.4.3 DEVELOPING COUNTRIES- 100
4.5 PATIENT ENROLMENT STRATEGIES- 102
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 106
4.7 CURRENT STATE OF ANTHRAX VACCINES 108
4.8 MIDDLE EAST & AFRICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 112
4.9 MIDDLE EAST & AFRICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 113
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEARS ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANYS PIPELINE FOR ANTHRAX TREATMENT. 117
6 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: REGULATIONS 119
7 MARKET OVERVIEW 123
7.1 DRIVERS 125
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 125
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 125
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 126
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 126
7.2 RESTRAINTS 127
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 127
7.2.2 FALSE DATA INTERPRETATION 128
7.3 OPPORTUNITIES 128
7.3.1 RISING PRODUCT LAUNCHES 128
7.3.2 RISING GOVERNMENT INITIATIVES 129
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 129
7.4 CHALLENGES 130
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 130
7.4.2 LACK OF SKILLED PROFESSIONALS 130
8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY TYPE 132
8.1 OVERVIEW 133
8.2 CUTANEOUS ANTHRAX 136
8.2.1 ANTIBIOTICS 137
8.2.1.1 BY DRUGS 137
8.2.1.1.1 CIPROFLOXACIN 138
8.2.1.1.2 LEVOFLOXACIN 138
8.2.1.1.3 DOXYCYCLINE 138
8.2.1.1.4 AMPICILLIN 138
8.2.1.1.5 OTHERS 138
8.2.1.2 BY PRODUCT TYPES 138
8.2.1.2.1 GENERICS 138
8.2.1.2.2 BRANDED 138
8.2.1.2.2.1 CIPRO 139
8.2.1.2.2.2 LEVO 139
8.2.1.2.2.3 DOXY 139
8.2.1.2.2.4 AMPICI 139
8.2.1.2.2.5 OTHERS 139
8.2.2 ANTITOXINS 140
8.2.2.1 RAXIBACUMAB 140
8.2.2.2 OBILTOXAXIMAB (ANTHIM) 140
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 140
8.2.2.4 OTHERS 140
8.2.3 VACCINES 141
8.2.3.1 RAXIBACUMAB 141
8.2.4 SURGERY 141
8.3 PULMONARY ANTHRAX 141
8.3.1 ANTIBIOTICS 142
8.3.1.1 BY DRUGS 143
8.3.1.1.1 CIPROFLOXACIN 143
8.3.1.1.2 LEVOFLOXACIN 143
8.3.1.1.3 DOXYCYCLINE 143
8.3.1.1.4 AMPICILLIN 143
8.3.1.1.5 OTHERS 143
8.3.1.2 BY PRODUCT TYPES 144
8.3.1.2.1 GENERICS 144
8.3.1.2.2 BRANDED 144
8.3.1.2.2.1 CIPRO 144
8.3.1.2.2.2 LEVO 145
8.3.1.2.2.3 DOXY 145
8.3.1.2.2.4 AMPICI 145
8.3.1.2.2.5 OTHERS 145
8.3.2 ANTITOXINS 145
8.3.2.1 RAXIBACUMAB 145
8.3.2.2 OBILTOXAXIMAB (ANTHIM) 145
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 145
8.3.2.4 OTHERS 146
8.3.3 VACCINES 146
8.3.3.1 RAXIBACUMAB 146
8.3.3.2 SURGERY 146
8.4 INTESTINAL ANTHRAX 146
8.4.1 ANTIBIOTICS 148
8.4.1.1 BY DRUGS 148
8.4.1.1.1 CIPROFLOXACIN 148
8.4.1.1.2 LEVOFLOXACIN 148
8.4.1.1.3 DOXYCYCLINE 148
8.4.1.1.4 AMPICILLIN 149
8.4.1.1.5 OTHERS 149
8.4.1.2 BY PRODUCT TYPES 149
8.4.1.2.1 GENERICS 149
8.4.1.2.2 BRANDED 149
8.4.1.2.2.1 CIPRO 150
8.4.1.2.2.2 LEVO 150
8.4.1.2.2.3 DOXY 150
8.4.1.2.2.4 AMPICI 150
8.4.1.2.2.5 OTHERS 150
8.4.2 ANTITOXINS 151
8.4.2.1 RAXIBACUMAB 151
8.4.2.2 OBILTOXAXIMAB (ANTHIM) 151
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 151
8.4.2.4 OTHERS 151
8.4.3 VACCINES 152
8.4.3.1 RAXIBACUMAB 152
8.4.3.2 SURGERY 152
9 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 153
9.1 OVERVIEW 154
9.2 PARENTERAL 157
9.3 ORAL 157
9.4 OTHERS 158
10 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY END USER 159
10.1 OVERVIEW 160
10.2 GOVERNMENT ORGANIZATION 163
10.3 HOSPITALS 163
10.4 ACADEMIC AND RESEARCH 164
10.5 OTHERS 166
11 MIDDLE EAST & AFRICA VIRTUAL REALITY MARKET, BY GEOGRAPHY 167
11.1 MIDDLE EAST AND AFRICA 168
11.1.1 SOUTH AFRICA 185
11.1.2 SAUDI ARABIA 194
11.1.3 UAE 203
11.1.4 EGYPT 212
11.1.5 ISRAEL 221
11.1.6 REST OF MIDDLE EAST AND AFRICA 230
12 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 231
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 231
13 SWOT ANALYSIS 232
14 COMPANY PROFILE 233
14.1 BAYER AG 233
14.1.1 COMPANY SNAPSHOT 233
14.1.2 REVENUE ANALYSIS 233
14.1.3 COMPANY SHARE ANALYSIS 234
14.1.4 PRODUCT PORTFOLIO 234
14.1.5 RECENT DEVELOPMENTS 234
14.2 PFIZER INC. 235
14.2.1 COMPANY SNAPSHOT 235
14.2.2 REVENUE ANALYSIS 235
14.2.3 COMPANY SHARE ANALYSIS 236
14.2.4 PRODUCT PORTFOLIO 236
14.2.5 RECENT DEVELOPMENTS 236
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 237
14.3.1 COMPANY SNAPSHOT 237
14.3.2 REVENUE ANALYSIS 237
14.3.3 COMPANY SHARE ANALYSIS 238
14.3.4 PRODUCT PORTFOLIO 238
14.3.5 RECENT DEVELOPMENT 238
14.4 SANOFI 239
14.4.1 COMPANY SNAPSHOT 239
14.4.2 REVENUE ANALYSIS 239
14.4.3 COMPANY SHARE ANALYSIS 240
14.4.4 PRODUCT PORTFOLIO 240
14.4.5 RECENT DEVELOPMENTS 240
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 241
14.5.1 COMPANY SNAPSHOT 241
14.5.2 REVENUE ANALYSIS 241
14.5.3 PRODUCT PORTFOLIO 242
14.5.4 RECENT DEVELOPMENT 242
14.6 ALEMBIC PHARMACEUTICALS LIMITED 243
14.6.1 COMPANY SNAPSHOT 243
14.6.2 PRODUCT PORTFOLIO 243
14.6.3 RECENT DEVELOPMENTS 243
14.7 ALTIMMUNE 244
14.7.1 COMPANY SNAPSHOT 244
14.7.2 REVENUE ANALYSIS 244
14.7.3 PRODUCT PORTFOLIO 245
14.7.4 RECENT DEVELOPMENTS 245
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 246
14.8.1 COMPANY SNAPSHOT 246
14.8.2 PRODUCT PORTFOLIO 246
14.8.3 RECENT DEVELOPMENTS 246
14.9 BLUEWILLOW BIOLOGICS. 247
14.9.1 COMPANY SNAPSHOT 247
14.9.2 PRODUCT PORTFOLIO 247
14.9.3 RECENT DEVELOPMENTS 247
14.10 DEINOVE 248
14.10.1 COMPANY SNAPSHOT 248
14.10.2 REVENUE ANALYSIS 248
14.10.3 PRODUCT PORTFOLIO 249
14.10.4 RECENT DEVELOPMENTS 249
14.11 EMERGENT 250
14.11.1 COMPANY SNAPSHOT 250
14.11.2 REVENUE ANALYSIS 250
14.11.3 PRODUCT PORTFOLIO 251
14.11.4 RECENT DEVELOPMENTS 251
14.12 ELUSYS THERAPEUTICS INC. 252
14.12.1 COMPANY SNAPSHOT 252
14.12.2 PRODUCT PORTFOLIO 252
14.12.3 RECENT DEVELOPMENTS 252
14.13 GC BIOPHARMA CORP. 253
14.13.1 COMPANY SNAPSHOT 253
14.13.2 REVENUE ANALYSIS 253
14.13.3 PRODUCT PORTFOLIO 254
14.13.4 RECENT DEVELOPMENTS 254
14.14 INDOCO REMEDIES LTD. 255
14.14.1 COMPANY SNAPSHOT 255
14.14.2 REVENUE ANALYSIS 255
14.14.3 PRODUCT PORTFOLIO 256
14.14.4 RECENT DEVELOPMENTS 256
14.15 INTEGRATED BIOTHERAPEUTICS, INC. 257
14.15.1 COMPANY SNAPSHOT 257
14.15.2 PRODUCT PORTFOLIO 257
14.15.3 RECENT DEVELOPMENTS 257
14.16 LUPIN. 258
14.16.1 COMPANY SNAPSHOT 258
14.16.2 REVENUE ANALYSIS 258
14.16.3 PRODUCT PORTFOLIO 259
14.16.4 RECENT DEVELOPMENTS 259
14.17 PARATEK PHARMACEUTICALS, INC. 260
14.17.1 COMPANY SNAPSHOT 260
14.17.2 REVENUE ANALYSIS 260
14.17.3 PRODUCT PORTFOLIO 261
14.17.4 RECENT DEVELOPMENTS 261
14.18 PORTON BIOPHARMA 262
14.18.1 COMPANY SNAPSHOT 262
14.18.2 PRODUCT PORTFOLIO 262
14.18.3 RECENT DEVELOPMENTS 262
14.19 SOLIGENIX 263
14.19.1 COMPANY SNAPSHOT 263
14.19.2 REVENUE ANALYSIS 263
14.19.3 PRODUCT PORTFOLIO 264
14.19.4 RECENT DEVELOPMENTS 264
14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 265
14.20.1 COMPANY SNAPSHOT 265
14.20.2 REVENUE ANALYSIS 265
14.20.3 PRODUCT PORTFOLIO 266
14.20.4 RECENT DEVELOPMENTS 266
14.21 ZYDUS GROUP 267
14.21.1 COMPANY SNAPSHOT 267
14.21.2 REVENUE ANALYSIS 267
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
